Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation.
The interaction of cis-diamminedichloroplatinum(II) (c-DDP) and irradiation was investigated in the RIF-1 tumor, skin and duodenum in C3H/Km mice. The c-DDP enhanced the effects of fractionated irradiation in the tumor, as measured by both growth delay and cell survival determined by excision and colony formation in vitro. This enhancement was at least additive and possibly supra-additive. The combined treatment was effective in clinically relevant treatment regimens. The same doses of c-DDP failed to enhance acute radiation skin reactions and caused only a moderate enhancement of the radiation-induced cell killing in duodenal crypt cells. The latter was found when c-DDP was administered immediately before each irradiation dose in a fractionated treatment schedule, but not when it was given in a single larger dose 24 h before the start of fractionated radiotherapy. Comparing the effects on tumor with those on normal tissues, the optimum treatment appeared to be c-DDP given once a week 24 h before daily fractionated irradiation.
D000818:Animals; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004386:Duodenum / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage; D012867:Skin / Q000187:drug effects / Q000528:radiation effects
D002945:Cisplatin